|
1
|
Thygesen K, Alpert JS, Jaffe AS, Chaitman
BR, Bax JJ, Morrow DA, et al: Fourth universal definition of
myocardial infarction (2018). Eur Heart J. 2018. View Article : Google Scholar
|
|
2
|
Nichols M, Townsend N, Scarborough P and
Rayner M: Cardiovascular disease in Europe 2014: Epidemiological
update. Eur Heart J. 35:2950–2959. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yeh RW, Sidney S, Chandra M, Sorel M,
Selby JV and Go AS: Population trends in the incidence and outcomes
of acute myocardial infarction. N Engl J Med. 362:2155–2165. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Writing Group Members, ; Mozaffarian D,
Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de
Ferranti S, Després JP, et al: Heart disease and stroke
statistics-2016 update: A report from the American Heart
Association. Circulation. 133:e38–e360. 2016.PubMed/NCBI
|
|
5
|
Talman V and Ruskoaho H: Cardiac fibrosis
in myocardial infarction-from repair and remodeling to
regeneration. Cell Tissue Res. 365:563–581. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ji P, Diederichs S, Wang W, Boing S,
Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, et
al: MALAT-1, a novel noncoding RNA, and thymosin beta4 predict
metastasis and survival in early-stage non-small cell lung cancer.
Oncogene. 22:8031–8041. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tripathi V, Ellis JD, Shen Z, Song DY, Pan
Q, Watt AT, Freier SM, Bennett CF, Sharma A, Bubulya PA, et al: The
nuclear-retained noncoding RNA MALAT1 regulates alternative
splicing by modulating SR splicing factor phosphorylation. Mol
Cell. 39:925–938. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang L, Lin C, Liu W, Zhang J, Ohgi KA,
Grinstein JD, Dorrestein PC and Rosenfeld MG: ncRNA- and Pc2
methylation-dependent gene relocation between nuclear structures
mediates gene activation programs. Cell. 147:773–788. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gutschner T, Hammerle M and Diederichs S:
MALAT1-a paradigm for long noncoding RNA function in cancer. J Mol
Med (Berl). 91:791–801. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Han Y, Liu Y, Zhang H, Wang T, Diao R,
Jiang Z, Gui Y and Cai Z: Hsa-miR-125b suppresses bladder cancer
development by down-regulating oncogene SIRT7 and oncogenic long
non-coding RNA MALAT1. FEBS Lett. 587:3875–3882. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang X, Li M, Wang Z, Han S, Tang X, Ge Y,
Zhou L, Zhou C, Yuan Q and Yang M: Silencing of long noncoding RNA
MALAT1 by miR-101 and miR-217 inhibits proliferation, migration,
and invasion of esophageal squamous cell carcinoma cells. J Biol
Chem. 290:3925–3935. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Michalik KM, You X, Manavski Y,
Doddaballapur A, Zornig M, Braun T, John D, Ponomareva Y, Chen W,
Uchida S, et al: Long noncoding RNA MALAT1 regulates endothelial
cell function and vessel growth. Circ Res. 114:1389–1397. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Puthanveetil P, Chen S, Feng B, Gautam A
and Chakrabarti S: Long non-coding RNA MALAT1 regulates
hyperglycaemia induced inflammatory process in the endothelial
cells. J Cell Mol Med. 19:1418–1425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao ZH, Hao W, Meng QT, Du XB, Lei SQ and
Xia ZY: Long non-coding RNA MALAT1 functions as a mediator in
cardioprotective effects of fentanyl in myocardial
ischemia-reperfusion injury. Cell Biol Int. 41:62–70. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lupfer C and Kanneganti TD: Unsolved
mysteries in NLR biology. Front Immunol. 4:2852013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Downs I, Vijayan S, Sidiq T and Kobayashi
KS: CITA/NLRC5: A critical transcriptional regulator of MHC class I
gene expression. Biofactors. 42:349–357. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kuenzel S, Till A, Winkler M, Hasler R,
Lipinski S, Jung S, Grötzinger J, Fickenscher H, Schreiber S and
Rosenstiel P: The nucleotide-binding oligomerization domain-like
receptor NLRC5 is involved in IFN-dependent antiviral immune
responses. J Immunol. 184:1990–2000. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Neerincx A, Jakobshagen K, Utermöhlen O,
Buning H, Steimle V and Kufer TA: The N-terminal domain of NLRC5
confers transcriptional activity for MHC class I and II gene
expression. J Immunol. 193:3090–3100. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yoshihama S, Roszik J, Downs I, Meissner
TB, Vijayan S, Chapuy B, Sidiq T, Shipp MA, Lizee GA and Kobayashi
KS: NLRC5/MHC class I transactivator is a target for immune evasion
in cancer. Proc Natl Acad Sci USA. 113:5999–6004. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chelbi ST and Guarda G: NLRC5, a promising
new entry in tumor immunology. J Immunother Cancer. 4:392016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bolha L, Ravnik-Glavač M and Glavač D:
Long noncoding RNAs as biomarkers in cancer. Dis Markers.
2017:72439682017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsang FH, Au V, Lu WJ, Shek FH, Liu AM,
Luk JM, Fan ST, Poon RT and Lee NP: Prognostic marker microRNA-125b
inhibits tumorigenic properties of hepatocellular carcinoma cells
via suppressing tumorigenic molecule eIF5A2. Dig Dis Sci.
59:2477–2487. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bayoumi AS, Park K-m, Wang Y, Teoh JP,
Aonuma T, Tang Y, Su H, Weintraub NL and Kim IM: A
carvedilol-responsive microRNA, miR-125b-5p protects the heart from
acute myocardial infarction by repressing pro-apoptotic bak1 and
klf13 in cardiomyocytes. J Mol Cell Cardiol. 114:72–82. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou H, Yu X and Zhou G: NLRC5 silencing
ameliorates cardiac fibrosis by inhibiting the TGFbeta1/Smad3
signaling pathway. Mol Med Rep. 16:3551–3556. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pasha Z, Haider HKh and Ashraf M:
Efficient non-viral reprogramming of myoblasts to stemness with a
single small molecule to generate cardiac progenitor cells. PLoS
One. 6:e236672011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gutschner T, Hammerle M, Eissmann M, Hsu
J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al:
The noncoding RNA MALAT1 is a critical regulator of the metastasis
phenotype of lung cancer cells. Cancer Res. 73:1180–1189. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang S, Yu W, Luo X, Chen J and Deng F:
MALAT1/miR-204/LC3-II: A potential regulated axis of autophagy in
myocardial ischemia-reperfusion injury. Int J Cardiol. 277:2222019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang S, Zhang L, Song J, Wang Z, Huang X,
Guo Z, Chen F and Zhao X: Long noncoding RNA MALAT1 mediates
cardiac fibrosis in experimental postinfarct myocardium mice model.
J Cell Physiol. 234:2997–3006. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Q, Lu G and Chen Z: MALAT1 promoted
cell proliferation and migration via MALAT1/miR-155/MEF2A pathway
in hypoxia of cardiac stem cells. J Cell Biochem. 120:6384–6394.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao J, Li L and Peng L: MAPK1
up-regulates the expression of MALAT1 to promote the proliferation
of cardiomyocytes through PI3K/AKT signaling pathway. Int J Clin
Exp Pathol. 8:15947–15953. 2015.PubMed/NCBI
|
|
31
|
Hou J, Zhou C, Long H, Zheng S, Guo T, Wu
Q, Wu H, Zhong T and Wang T: Long noncoding RNAs: Novel molecules
in cardiovascular biology, disease and regeneration. Exp Mol
Pathol. 100:493–501. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Paraskevopoulou MD and Hatzigeorgiou AG:
Analyzing MiRNA-LncRNA Interactions. Methods Mol Biol.
1402:271–286. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chang SM and Hu WW: Long non-coding RNA
MALAT1 promotes oral squamous cell carcinoma development via
microRNA-125b/STAT3 axis. J Cell Physiol. 233:3384–3396. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Motta V, Soares F, Sun T and Philpott DJ:
NOD-like receptors: Versatile cytosolic sentinels. Physiol Rev.
95:149–178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Benko S, Magalhaes JG, Philpott DJ and
Girardin SE: NLRC5 limits the activation of inflammatory pathways.
J Immunol. 185:1681–1691. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kobayashi KS and van den Elsen PJ: NLRC5:
A key regulator of MHC class I-dependent immune responses. Nat Rev
Immunol. 12:813–820. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Biswas A, Meissner TB, Kawai T and
Kobayashi KS: Cutting edge: Impaired MHC class I expression in mice
deficient for Nlrc5/class I transactivator. J Immunol. 189:516–520.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yao Y, Wang Y, Chen F, Huang Y, Zhu S,
Leng Q, Wang H, Shi Y and Qian Y: NLRC5 regulates MHC class I
antigen presentation in host defense against intracellular
pathogens. Cell Res. 22:836–847. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ma SR and Xie XW: NLRC5 deficiency
promotes myocardial damage induced by high fat diet in mice through
activating TLR4/NF-κB. Biomed Pharmacother. 91:755–766. 2017.
View Article : Google Scholar : PubMed/NCBI
|
